Namilumab, but not infliximab, showed proof-of-concept evidence for reduction in inflammation—as measured by CRP concentration—in hospitalised patients with COVID-19 pneumonia. Namilumab should be prioritised for further investigation in COVID-19.
The 14 Assemblies of the ATS will hold membership meetings in San Diego on Sunday, May 19, and Monday, May 20, during the International Conference.…
Severe community-acquired pneumonia (SCAP) is a major concern worldwide as it is a leading cause of morbidity and mortality. The increasing incidence of mult…
Drs. Khushboo Goel and Kathryn del Valle have a conversation with Drs. Stephen Chan and Andrea Frump, Pulmonary Circulation Assembly Programming Chairs for the ATS…
We are the Perelman School of Medicine — the Nation’s First — and the Hospital of the University of Pennsylvania — the nation’s first hospital…
Meet Garrie Farrow and learn her story of living with Sarcoidosis, and the impact of her sister Sharon’s similar journey. Their story is featured in…
